The Protective Effect of Ginkgo Biloba Extract on Cisplatin-induced Ototoxicity in Humans
Launched by UNIVERSITY OF BRASILIA · Jun 7, 2010
Trial Information
Current as of May 30, 2025
Completed
Keywords
ClinConnect Summary
The ototoxicity is an alteration caused by drugs that compromises the auditory and vestibular functions. The cisplatin (CDDP) is a potent antineoplastic agent used for the treatment of cancer in both adults and children although it has several side effects. Current opinion is that cisplatin ototoxicity occurs due to alterations in the antioxidant system of the outer hair cells (OHC) of the cochlea. The distortion-product otoacoustic emissions (DPOAE) has been showed to be a sensitive test for diagnosis of OHC injury and has been used for monitoring treatment with ototoxic drugs. Because of ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Over the age of eighteen
- • Patients that will begin treatment with cisplatin
- • No prior treatment with cisplatin
- Exclusion Criteria:
- • Individuals with middle ear, cochlear or retrocochlear disease
- • Presence of changes in pure tone audiometry and/or distortion-product otoacoustic emissions
About University Of Brasilia
The University of Brasília is a prestigious academic institution dedicated to advancing medical research and education. As a clinical trial sponsor, it leverages its extensive resources and expertise to facilitate innovative research initiatives aimed at improving healthcare outcomes. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring the highest standards of ethical conduct and scientific rigor in its trials. With a commitment to addressing pressing health challenges and contributing to the global body of medical knowledge, the University of Brasília plays a pivotal role in the advancement of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brasília, Df, Brazil
Patients applied
Trial Officials
Mirela A Dias
Principal Investigator
University of Brasilia
Carlos CP Oliveira
Study Chair
University of Brasilia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials